Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center

: Neuroendocrine tumors (NETs) are rare neoplasms. Approximately 75% of all cases manifest in the gastroenteropancreatic (GEP) system. Because of the low incidence of NETs, limited data about the clinical outcome and prognostic variables are available. In an attempt to identify prognostic parameters...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2004-04, Vol.1014 (1), p.222-233
Main Authors: PAPE, ULRICH-FRANK, BÖHMIG, MICHAEL, BERNDT, UTA, TILING, NIKOLAUS, WIEDENMANN, BERTRAM, PLÖCKINGER, URSULA
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
carcinoid
chemotherapy
Female
Follow-Up Studies
Gastrointestinal Neoplasms - mortality
Gastrointestinal Neoplasms - pathology
Gastrointestinal Neoplasms - therapy
Germany - epidemiology
Humans
Incidence
interferon-alpha
Male
metastasis
Middle Aged
neuroendocrine tumor
Neuroendocrine Tumors - mortality
Neuroendocrine Tumors - pathology
Neuroendocrine Tumors - therapy
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - therapy
Referral and Consultation
Retrospective Studies
somatostatin-analogue
surgery
survival
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: Neuroendocrine tumors (NETs) are rare neoplasms. Approximately 75% of all cases manifest in the gastroenteropancreatic (GEP) system. Because of the low incidence of NETs, limited data about the clinical outcome and prognostic variables are available. In an attempt to identify prognostic parameters, we investigated the distribution of primary tumors, pattern of metastasis formation, clinical presentation, histological classification, and outcome of therapeutic interventions in a large patient cohort cared for in a German referral center. In 254 patients with GEP‐NETs, the primary tumor was of foregut, midgut, or hindgut origin in 44.1% (28.7% pancreas), 43.7% (34.7% jejunoileum), and 4.3%, respectively. No primary tumor was found in 7.9%. Metastases occurred preferentially in lymph nodes and the liver. The overall 5‐year survival rate was 57.1%. In the absence or presence of metastases at initial diagnosis the 5‐year survival rate was 80.0% and 51.7%, respectively. The 5‐year survival rate was related to the localization of the primary and was 75.0% and 42.9% for jejunoileal and pancreatic tumors, respectively. The size of the primary tumor (
ISSN:0077-8923
1749-6632
DOI:10.1196/annals.1294.025